U.S. Markets open in 3 hrs 11 mins

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
83.61+0.34 (+0.41%)
At close: 4:15PM EDT

83.63 +0.02 (0.02%)
Pre-Market: 6:04AM EDT

People also watch
CELGBIIBAMGNBMYREGN
Full screen
Previous Close83.27
Open83.41
Bid82.75 x 800
Ask83.64 x 100
Day's Range82.86 - 84.28
52 Week Range63.76 - 86.27
Volume8,473,407
Avg. Volume9,344,542
Market Cap109.19B
Beta0.91
PE Ratio (TTM)9.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (2.53%)
Ex-Dividend Date2017-09-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com15 hours ago

    [$$] Getting Ready for Gilead's CAR-T

    Guggenheim Securities This report includes results from our proprietary survey regarding the potential early demand for chimeric antigen receptor T-cell (CAR-T) therapy. The survey includes responses from 25 hematologists/oncologists regarding the prospective use of CAR-T therapy in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) patients. The survey had begun prior to Gilead Sciences’ (GILD) announced acquisition of Kite Pharma (KITE) on Aug. 28 of this year.

  • Barrons.com19 hours ago

    Now That Gilead's Bought Kite, Are Doctors Ready To Use CAR T Cancer Therapy?

    In the fight against cancer, CAR T therapies are growing in popularity. Butler and Cha surveyed 25 hematologists/oncologists about their thoughts on potentially using CAR T therapy in appropriate patients within their practices, beginning before the Gilead-Kite Pharma deal was announced, and the results appear to be good news. From the note: Our findings suggest that the majority of surveyed hematologists/oncologists are familiar with CAR T therapy, and plan to use the therapy for either r/r ALL [relapsed and refractory acute lymphoblastic leukemia] or r/r DLBCL [diffuse large B-cell lymphoma] patients.

  • Oddly, Juno Therapeutics Is Jumping 11.3% Today
    Motley Fool4 days ago

    Oddly, Juno Therapeutics Is Jumping 11.3% Today

    Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.